COYA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs)...

Stats
Today's Volume	32 527.00
Average Volume	83 774.00
Market Cap	111.39M
EPS	$0 ( 2024-05-08 )
Next earnings date	( $0 ) 2024-08-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.86
ATR14	$0.0570 (0.74%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-22	Lee Ann	Buy	1 000	Common Stock, par value $0.0001 per share
2024-01-31	Grossman Fred	Buy	81 819	Stock Option (right to buy)
2024-01-31	Grossman Fred	Buy	74 069	Stock Option (right to buy)
2024-01-31	Snyder David S	Buy	81 819	Stock Option (right to buy)
2024-01-31	Berman Howard	Buy	189 680	Stock Option (right to buy)

INSIDER POWER
88.19
Last 39 transactions
Buy: 1 037 435 \| Sell: 190 798

Volume Correlation

Long: 0.31 (neutral)

Short: 0.37 (neutral)

Signal:(61.278) Neutral

Coya Therapeutics, Inc. Correlation

10 Most Positive Correlations
OZEM	1
PRFX	0.896
NA	0.877
ROMA	0.875
ARKVX	0.867
PAVS	0.867
LSTOX	0.866
DYFI	0.866
HTOO	0.866
GDMOX	0.861

10 Most Negative Correlations
RFAIU	-0.934
NEWZ	-0.904
ISRL	-0.869
ANSC	-0.868
IPXX	-0.861
BAYA	-0.851
FORL	-0.85
BKHAU	-0.846
BKHA	-0.838
AACIW	-0.819

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Coya Therapeutics, Inc. Correlation - Currency/Commodity

0.07
( neutral )

0.16
( neutral )

0.00
( neutral )

0.16
( neutral )

0.08
( neutral )

0.21
( neutral )

Coya Therapeutics, Inc. Financials

Annual	2023
Revenue:	$6.00M
Gross Profit:	$5.97M (99.54 %)
EPS:	$-0.790

FY	2023
Revenue:	$6.00M
Gross Profit:	$5.97M (99.54 %)
EPS:	$-0.790

FY	2022
Revenue:	$0
Gross Profit:	$-27 361.00 (0.00 %)
EPS:	$-1.480

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.260

Financial Reports:

No articles found.

Coya Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Coya Therapeutics, Inc.

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company\'s product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company\'s product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.